Antibody-driven therapy of AML

Sergio Amadori Tor Vergata University Hospital Roma


Roma, 09/2017




Chairmen: F. Lo-Coco, M.A. Sanz Honorary President: F. Mandelli


Disclosures of SERGIO AMADORI

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Amgen						x	
Celgene						x	
Daiichi- Sankyo						x	
Janssen						x	
Novartis						x	





Selected antigen targets for therapy in AML




Buckley and Walter, Hematology 2015

The quest for novel AML antigens continues...

"The ideal target antigen"


- High level of expression on all AML cells including LSCs
- Minimal to no expression in normal tissues
- Important role in AML pathogenesis
- Not shed into the circulation
- Sufficiently immunogenic (in case of active immunization strategies)



Targeting CD33

Myeloid differentiation antigen broadly expressed in AML (> 90% of pts)¹ Gemtuzumab Vadastuximab In some myeloid leukemias, CD33 thought to be expressed on LSCs² ²²⁵Ac-**AMG330** Lintuzumab **CD33** Function of CD33 poorly understood (cell adhesion and activation)

¹Pollard JA et al, Blood 2012; ²Walter RB et al, Blood 2012




GO + Induction chemotherapy

First antibody-targeted agent for the treatment of AML

CR/CRp rate 30%; rare VOD/SOS

Approved for older adults in first relapse in 2000

Withdrawn from market in 2010




Hills et al, Lancet Oncol 2014

GO+IC: meta-analysis of RCT

Trial	GO dose/sched	Induction Chemo	No. of patients	Median age (years)	CG Risk (MRC)	
MRC AML15	3 mg/m ² d1	ADE,DA, FLAG-Ida	1099	50 (15-71)	All	
NCRI AML16	5 mg/m- ui	DA, DClo	1115	67 (51-84)	All	
SWOG-0106		DA (3+7)	595	47 (18-60)	All	
GOELAMS AML2006/IR	6 mg/m ² d4	DA (3+7)	238	50.5 (18-60)	Inter	
ALFA-0701	3 mg/m ² d1,4,7	DA (3+7)	278	62 (50-70)	Inter/Adv	


Overall Survival




Relapse


	Events/patients		o-e Variance			OR (CI*)	
	Gemtuzumab ozogamicin group	No gemtuzumab ozogamicin group					
3 mg/m² single dose							
MRC AML15	282/466	314/478	-20.8	148.8		0.87 (0.70-1.07)	
NCRIAML16	325/396	321/376	-27.2	159-5		0.84 (0.69-1.03)	
Subtotal	607/862	635/854	-48.0	308-2	\$	0.86 (0.77-0.96)	0.006
Test for heterogeneity betwe	een trials χ²=0·1; p=0·8						
3 mg/m ² fractionated							
ALFA-0701	51/113	69/104	-19.1	28.7	∎ ¦	0.51 (0.32-0.83)	
Subtotal	51/113	69/104	-19-1	28.7	\triangleleft	0.51 (0.36-0.74)	0.0004
6 mg/m² dose							
GOELAMS AML2006 IR	43/109	48/102	-4.9	22.7		0.81 (0.47-1.39)	
SWOG 0106	118/222	122/222	-2.5	59.9	-	0.96 (0.69–1.34)	
Subtotal	161/331	170/324	-7.4	82.6		0.91 (0.74–1.14)	0-4
Test for heterogeneity betwe	een trials χ²=0·5; p=0·5						
Total	819/1306	874/1282	-74.4	419-5	4	0-84 (0-76-0-92)	0.0003
Test for heterogeneity (five t	rials) χ ² =8-2; p=0-08						
Test for heterogeneity betwe		2		0-1	1·0	10-0	
					Favours Favours gemtuzumab gemtuzu	mab	
					ozogamicin ozogam	icin	

Survival by cytogenetics





Vadastuximab talirine



¹Sutherland et al, Blood 2013; ²Sutherland et al, ASH 2014; ³Stein et al, ASH 2014

VT: early studies in ND-AML

¹Phase 1 single agent (older pts)

- N=26 (median 74y) treated at 40 mcg/kg q3wk x 2 cycles
- CR+CRi 54% (46% MRDneg by flow)
- 30/60-d mortality 0%15%, no VOD

Phase 1 in combo with HMA
All on solution of the second state of the second

¹Bixby DL et al, ASH 2016; ²Ravandi F et al, EHA 2017; ³Levy MY et al, EHA 2017


Targeting CD123

CD123 (IL-3 receptor α chain) is a key mediator of cell proliferation, differentiation and suvival

Expressed on >90% in LSCs in nearly 90% of AML patient samples

Very low expression on normal HSCs

Promising target for antibody therapy of AML




Macauley MS et al, Nat Rev Immunol 2014

Talacotuzumab (JNJ-56022473) Novel Anti-CD123 antibody with enhanced ADCC function Single agent safety observed in AML pts in CD16 CR/CRp at high risk of CD123 relapse (phase 1)¹ AML Cell Killing (A) Decitabine p<0.001 8 Untreated Treated rMFI Ratio (CD123+ Expression) 7 6 DAC (3-5 days) 5 p<0.001 4 increases CD123 3 p=0.132 expression² p=0.004 2 1 0 24 h treatment 48 h treatment 3 h tx, 5 h WO (3 days) 1 h tx, 23 h WO (5 days) ¹Smith BD et al, Blood 2014; ²Syed K et al, ASH 2015

DAC + TALA study

A Randomized Phase 2/3 Study of Decitabine Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine Alone in Patients With AML Ineligible for Intensive Chemotherapy



Targeting CD45

CD45 (LCA) is a tyrosine phosphatase expressed at high density on lymphohematopoietic cells

Not expressed on nonhematopoietic tissues


Some 85% to 90% of acute leukemias express CD45

Anti-CD45 radioimmunoconjugates in clinical development as part of RIC-HSCT for patients with advanced AML

Lomab-B

- Combines anti-CD45 MoAb with a radionuclide (β-emitting ¹³¹I)
- Offers target-specific ablation as a conditioning regimen prior to HSCT
- Directs radiation to leukemic and immune cells
- Does not bind other normal tissues

Pagel JM et al, Blood 2009




Targeting immune checkpoints

Tumors take advantage of immune checkpoints as mechanism of immune evasion¹

PD-1/PD-L1 axis upregulated in AML (poor prognosis)²

Clinical evaluation of PD-1/PD-L1 blockade in AML ongoing



¹Pardoll DM , Nat Rev Cancer 2012; ²Yang H et al, Leukemia 2013


Nivolumab: an anti-PD-1 MoAb

HMAs upregulate PD-1 and PD-L1 genes promoting resistance to epigenetic therapy


PD-1/PD-L1 blockade may improve response and abrogate resistance to HMAs

Nivolumab (OPDIVO) is a fully human MoAb that binds PD-1

PD-1 or PD-L1 Blockade Stimulates anti-tumor T cell response




AZA + NIVO (phase 1b/2)




Daver N et al, EHA 2017

Outcomes (N=70)

Best response / Outcome	N (%) / Med [Range]		
Evaluable	70		
ORR	22 (32)		
CR/CRi	15 (22)		
HI + 50% blast reduction (6mo+)	7 (10)		
50% reduction in blast	17 (24)		
Progression/ <u>Stable dis (6 mo+)</u>	26 (37) [21/ <u>5]</u>		
8-week mortality	5 (7)		
Median cycles to response	2 [1 - 13]		
Median follow-up	8.6 mo [2.8 – 21.3]		



Response Total Died Median



Conclusions

Newer, more effective treatment strategies are needed to improve outcomes of patients with AML

There are multiple promising targets for antibody development in AML therapy (CD33, CD123, CD47, CD45, CLL-1, immune checkpoint)

Several agents targeting these antigens have shown promising efficacy and tolerability in early phase studies and are rapidly moving into phase 3 trials (VT, TALA, Lomab-B)

Combinations of novel antibodies with chemotherapy are being explored in AML